Recurrent unresectable or metastatic nasopharyngeal carcinoma

Active Ingredient: Toripalimab

Indication for Toripalimab

Population group: only adults (18 years old or older)

Therapeutic intent: Curative procedure

Toripalimab is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments:

3 mg/kg every 2 weeks until disease progression or unacceptable toxicity

For:

Dosage regimens

Intravenous, 3 milligrams toripalimab per kilogram of body weight, once every 2 weeks.

Dosage considerations

Administer diluted solution intravenously via an infusion pump using an in-line aseptic filter.
First Infusion: Infuse over at least 60 minutes.
Subsequent infusions: If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes.
Do not co-administer other drugs through the same intravenous line.
When administered on the same day as chemotherapy, toripalimab should be administered prior to chemotherapy.
Refer to the Prescribing Information for cisplatin and gemcitabine for recommended dosing information.

Active ingredient

Toripalimab
Toripalimab is a humanised IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation, cytokine production, and cytotoxic activity. Read more about Toripalimab

Related medicines

Structured Product Labeling (SPL/PLR) 2024: LOQTORZI Solution for injection

Summary of Product Characteristics (SPC) 2025: LOQTORZI Concentrate for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.